Immune Monitor - August 2018

A Message from the President

Dear Colleagues,

Cancer immunotherapy education is important even in the summertime. The FDA continues to grant immunotherapeutic approvals in new disease states, as well as integrate tumor biomarker status into indications. The most recent examples of approvals include pembrolizumab for PD-L1-positive cervical cancer patients and combination nivolumab and ipilimumab for patients with MSI-H/dMMR-positive colorectal cancer.

Therefore, Society for Immunotherapy of Cancer (SITC) will soon begin the sixth year of its Advances in Cancer Immunotherapy™ (ACI) series. These regional education programs based in academic medical centers and in online education provide opportunities for healthcare professionals – particularly those in the community setting – to get up to date on immunotherapy and discuss patient management.  SITC will host 15 ACI programs throughout the United States and Canada during the 2018-19 series featuring disease-specific sessions on lung cancer, melanoma, head and neck cancers, genitourinary cancers and hematologic malignancies. These 4.5-hour programs are CME-, CNE- and CPE-certified programs presented by the local experts in tumor immunology and cancer immunotherapy. Clinicians, students and patient advocates may attend for free. Note that registration is now open for the ACI in Madison, Wis. (Sept. 6, 2018) and Boston, Mass. (Sept. 27, 2018) (we’ll continue to announce future dates and locations). The Sept. 6 ACI will also be live streamed, so you can attend from wherever you are!

On July 17, SITC published the highly anticipated, “The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC),” the society’s sixth manuscript of the series, in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal. The guideline includes recommendations on treatment scheduling concerning the most recent U.S. FDA-approved immunotherapies, a discussion about late-breaking data from 2018, the use of predictive biomarkers including PD-L1 and tumor mutational burden and managing immune-related adverse events. A big thank you and congratulations to the SITC Cancer Immunotherapy Guidelines NSCLC Subcommittee, chaired by Roy Herbst, MD, PhD (Yale Cancer Center), and co-chaired by Julie Brahmer, MD (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins), Ramaswamy Govindan, MD (Washington University School of Medicine), and Naiyer Rizvi, MD (Columbia University Medical Center), for this important contribution to the field.

SITC will host a one-hour, free webinar on Thursday, Sept. 13 at 1 p.m. EDT, featuring members of the NSCLC Subcommittee. This webinar will review the guidelines and provide a unique Q&A forum between participants and faculty.

Lastly, SITC is about to announce a new educational initiative that I am particularly excited about, the “2019 SITC Winter School.” Planned for February 2019 in Phoenix, Ariz., SITC Winter School will educate early career scientists and physicians about the core principles of cancer immunotherapy, biomarker technologies, clinical trial design, grant writing and more, over an intensive and interactive five-day program.

I hope that you all enjoy the rest of your summer.  It’s a great time to catch up on all things immunotherapy!

ButterfieldOct2016_2_57433.jpg
 
Lisa H. Butterfield, PhD
SITC President


SITC Cancer Immunotherapy Guidelines-Non-Small Cell Lung Cancer Manuscript Published

On July 17, SITC published its highly anticipated consensus treatment recommendations for non-small cell lung cancer in the Journal for ImmunoTherapy of Cancer (JITC). The NSCLC manuscript is the sixth of in the society’s Cancer Immunotherapy Guidelines series.

Other disease states published as part of the SITC Cancer Immunotherapy Guidelines series include:

 Work is currently underway to produce new Guidelines for head and neck cancers, with updates in progress for acute leukemia and renal cell carcinoma. Learn more about SITC’s Cancer Immunotherapy Guidelines.

Attend Upcoming Free NSCLC Guidelines Webinar

Oncologists, nurses and other members of the cancer care team are invited to participate in a free SITC webinar about the recently published Cancer Immunotherapy Guidelines on non-small cell lung cancer on Thursday, Sept. 13, 2018 at 1 p.m. EDT.

The following co-authors of the SITC Cancer Immunotherapy Guidelines-NSCLC manuscript will present and lead a question-and-answer session with participants during the free webinar:

      • Julie R. Brahmer, MD  – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      • Patrick Forde, MD – Johns Hopkins University
      • Scott N. Gettinger, MD – Yale Cancer Center
      • Roy S. Herbst, MD, PhD – Yale Cancer Center 

Details of this webinar, including how attendees can register, are available on the SITC website, SITC Cancer Immunotherapy CONNECT.

Attend an Upcoming Advances in Cancer Immunotherapy™ Program

SITC is excited to kick off the 2018-19 series of its Advances in Cancer Immunotherapy™ (ACI) regional education programs, which includes an opportunity for clinicians around the world to attend via webcast.

The following dates and times have been confirmed for the upcoming ACI series:

Date ACI Program Location Registration
Thursday, Sept. 6 Madison, Wis. Register Here
Thursday, Sept. 6 Live Webcast Register Here
Thursday, Sept. 27 Boston, Mass. Register Here
Thursday, Oct. 25, 2018 Indianapolis, Ind. Coming Soon!
Saturday, Nov. 3, 2018 Seattle, Wash. Coming Soon!
Thursday, Dec. 6, 2018 Louisville, Ky. Register Here
Saturday, Dec. 15, 2018 Pittsburgh, Penn. Register Here



The 4.5-hour programs are CME-, CNE- and CPE-certified programs presented by local authorities in tumor immunology and cancer immunotherapy. The programs are free for healthcare professionals in a clinical setting, students and patient advocates.

Attendees will leave these programs with the ability to:

      • Understand FDA-approved immunotherapy treatments for specific disease states, including checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines
      • Identify and manage immune-related adverse events
      • Employ strategies to overcome operational and reimbursement barriers to incorporating immunotherapy into your practice
      • Apply foundational knowledge for optimized clinical implementation of SITC’s Cancer Immunotherapy Guidelines Connect with regional immunotherapy experts

The ACIs will include sessions dedicated to lung cancer, melanoma, head and neck cancers, genitourinary cancers and hematologic malignancies. Attend an upcoming ACI to improve your understanding of the basic principles of cancer immunotherapy while learning important trends, new developments and potential future approvals for the future of the field.

Earn Continuing Education Credit in ACI 2017 Video Series

As the 2018-19 ACI series beckons, refresh your understanding of basic principles of cancer immunotherapy and more via exemplar video presentations from the 2017-18 series.

Available free of charge via SITC Cancer Immunotherapy connectED, the society’s online learning portal, the Advances in Cancer Immunotherapy™ 2017 Video Series features 12 online modules to help facilitate your understanding of the clinical applications of immunotherapy for disease states with FDA-approved treatments and much more.

Click any of the following module links to earn your free CME, CNE or CPE credits today:

Access Enduring Materials from past ACIs

Watch past presentations from an ACI program and access enduring materials from the 2017-18 series by clicking the following links through your free SITC CONNECT account:

2017-18 ACI Program Program Date
Advances in Cancer Immunotherapy™ – Buffalo, NY March 24, 2018
Advances in Cancer Immunotherapy™ – Miami, FL March 10, 2018
Advances in Cancer Immunotherapy™ – Dallas, TX March 3, 2018
Advances in Cancer Immunotherapy™ – Charleston, SC Feb. 24, 2018
Advances in Cancer Immunotherapy™ – Durham, NC Feb. 9, 2018
Advances in Cancer Immunotherapy™ – Atlanta, GA Jan. 19, 2018
Advances in Cancer Immunotherapy™ – Houston, TX Dec. 2, 2017
Advances in Cancer Immunotherapy™ – Washington, D.C. Oct. 7, 2017
Advances in Cancer Immunotherapy™ – Boston, MA Oct. 5, 2017
Advances in Cancer Immunotherapy™ – New Haven, CT Sept. 16, 2017
Advances in Cancer Immunotherapy™ – Pittsburgh, PA Sept. 14, 2017
Advances in Cancer Immunotherapy™ – Milwaukee, WI Aug. 12, 2017
Advances in Cancer Immunotherapy™ – Philadelphia, PA Aug. 4, 2017
Advances in Cancer Immunotherapy™ – Los Angeles, CA June 29, 2017
Advances in Cancer Immunotherapy™ – San Francisco, CA May 6, 2017